Search results
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to...
The Longview News-Journal· 4 days ago- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 23 hours agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued ...
AbbVie shares hold Buy rating with $180 target from TD Cowen By Investing.com
Investing.com· 2 days agoOn Tuesday, TD (TSX:TD) Cowen maintained a positive stance on AbbVie Inc . TD Cowen adjusted its...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via AOL· 11 hours agoOn Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical...
AbbVie Inc. (NYSE:ABBV) Receives $174.31 Average Target Price from Brokerages
ETF DAILY NEWS· 5 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are presently covering ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoNEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference
In RA Treatment, Don't Overlook Underlying CV Risks
Medscape· 20 hours agoPatients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated...
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
BioPharma Dive via Yahoo Finance· 4 days agoGoldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be...
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further...
Digital Journal· 2 days agoBioRestorative is not the only pharmaceutical company interested in the medical aesthetics market; companies like AbbVie , Cynosure and Sisram Medical are ...
Piramal Pharma Limited Announces Results for Q4 and FY2024
The Pilot News· 6 days agoPiramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter ...